Sepsis News and Research

Latest Sepsis News and Research

Hormone involved in iron metabolism can save mice from deadly acute inflammation: Scientists

In a surprising discovery that someday may lead to new treatments for many inflammatory diseases, University of Utah scientists found that a hormone involved in iron metabolism can save mice from deadly acute inflammation.

8 Jun 2010

Allos Therapeutics reports data from PROPEL trial of FOLOTYN in patients with PTCL

Allos Therapeutics, Inc. today reported new analyses of data from the Company's pivotal PROPEL trial of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma.

7 Jun 2010

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

Results of a Phase III study presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's eribulin mesylate significantly improved median overall survival (OS) compared with Treatment of Physician's Choice (TPC) in heavily pre-treated metastatic breast cancer patients.

7 Jun 2010

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy.

4 Jun 2010

SOGC urges strategy for preventing deaths during delivery, childbirth

As the G8 approaches, the Society of Obstetricians and Gynaecologists of Canada (SOGC) is urging the Canadian government to recognize that a strategy on maternal and child health must focus on preventing deaths during delivery and childbirth as 80% of maternal deaths in low-resource countries take place at that time.

4 Jun 2010

Allos Therapeutics' FOLOTYN data to be presented at 46th ASCO and 15th EHA Congress

Allos Therapeutics, Inc. today announced that data on FOLOTYN® (pralatrexate injection) will be presented at two upcoming medical conferences: the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), which will be held June 4-8 in Chicago, Illinois, and at the 15th Congress of the European Hematology Association (EHA), which will be held June 10-13 in Barcelona, Spain.

2 Jun 2010

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on novel monoclonal antibodies against toxins produced by the bacterium Clostridium difficile (C. difficile). The monoclonal antibodies effectively neutralized the cell-killing activities of the toxins in vitro and significantly improved survival in a stringent animal model of C. difficile infection. C. difficile is the leading cause of hospital-acquired diarrhea in the United States and represents a growing global public health challenge.

28 May 2010

Genzyme's Lumizyme for Pompe disease receives FDA marketing approval

Genzyme Corporation announced today that the FDA has granted U.S. marketing approval for Lumizyme™ (alglucosidase alfa), produced at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. Lumizyme is the first treatment approved in the United States specifically to treat patients with late-onset Pompe disease.

25 May 2010

Pregnant women with H1N1 flu strain are at risk for obstetrical complications: Study

Pregnant women who contract the H1N1 flu strain are at risk for obstetrical complications including fetal distress, premature delivery, emergency cesarean delivery and fetal death, according to a report in the May 24 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

25 May 2010

British Columbia first in Canada to include Prevnar 13 in routine child immunization program

British Columbia is leading the way in vaccinations to protect children from serious disease. The province is the first in Canada to include Prevnar 13, the vaccine that provides the broadest coverage available against Streptococcus pneumoniae that may cause invasive pneumococcal disease, in the routine child immunization program.

21 May 2010

Tel Aviv University researcher develops tool to measure tissue damage in bed-ridden, paralyzed patients

There's currently no reliable tool to help prosthetic developers fit artificial limbs without ensuing discomfort or pain, or tell medical personnel when bed-ridden patients need to be moved to avoid bedsores and other problems.

19 May 2010

Human stem cells restore alveolar epithelial tissue after E. coli endotoxin-induced ALI: Researchers

Human stem cells administered intravenously can restore alveolar epithelial tissue to a normal function in a novel ex vivo perfused human lung after E. coli endotoxin-induced acute lung injury, according to research from the University of California San Francisco.

18 May 2010

BioMS reports consolidated net income of $6.5M for first-quarter 2010 compared to net loss of $3.8M in 2009

BioMS Medical Corp., today announced financial and operational results for the three months ended March 31, 2010.

15 May 2010

Experts address fundamental questions related to renal failure in ICU

Despite the fact that recent medical advances have allowed healthcare professionals to stabilize patients who would have otherwise died, many stabilized patients later develop organ system failure. In fact, acute renal failure is one of the biggest threats to critically ill patients: forty percent of patients with this condition die.

14 May 2010

MRSA Survivors Network to raise awareness on MRSA infections

More Americans die annually from invasive methicillin-resistant Staphylococcus aureus infections than from HIV/AIDS, H1N1 influenza and Parkinson's disease, yet the United States and many other countries' health officials continue to ignore the global crisis.

12 May 2010

Benefits outweigh risks in myeloablative therapy for children with high-risk neuroblastoma

Neuroblastoma is among the most common of childhood cancers and fortunately, some children will get better spontaneously. Yet for children with high-risk disease the outlook is poor: more than half will relapse despite chemotherapy.

12 May 2010

Opinions: Abortion in Canada's G8 initiative; Security of Afghan women; U.S. global development strategy; Mother's Day; U.S. food security initiative; Polio eradication

National Post columnist Jonathan Kay examines the ongoing debate over whether Canada's G8 child and maternal health initiative should include abortions, which according to a 2006 Oxford University Press-World Bank report, are "one small chunk of a bigger puzzle. A much larger problem, in terms of the number of female lives affected, is the decidedly less headline-grabbing subject of hemorrhages - which include antepartun hemorrhages … and primary postpartum hemorrhages.

12 May 2010

Astute Medical completes $26.5 million series B financing

Astute Medical, Inc., a developer of novel, biomarker-based medical diagnostics, today announced completion of a $26.5 million series B financing co-led by Domain Associates and Delphi Ventures. Astute will use the funding to advance research and development aimed at the identification and validation of protein biomarkers with the goal of commercializing high potential diagnostic products.

10 May 2010

Lancet examines Canada's G8 strategy for maternal, child health initiatives

A Lancet World Report examines the details of the Canadian government's strategy for the G8 maternal and child health initiative and reactions from global health leaders and politicians to the plan, including the announcement during a meeting of G8 leaders Halifax, Nova Scotia, that the initiative would not support abortion.

10 May 2010

Allos Therapeutics reports net loss of $20.5 million for first-quarter 2010

Allos Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2010.

6 May 2010

Sepsis News and Research

Latest Sepsis News and Research

Hormone involved in iron metabolism can save mice from deadly acute inflammation: Scientists

Allos Therapeutics reports data from PROPEL trial of FOLOTYN in patients with PTCL

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

SOGC urges strategy for preventing deaths during delivery, childbirth

Allos Therapeutics' FOLOTYN data to be presented at 46th ASCO and 15th EHA Congress

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

Genzyme's Lumizyme for Pompe disease receives FDA marketing approval

Pregnant women with H1N1 flu strain are at risk for obstetrical complications: Study

British Columbia first in Canada to include Prevnar 13 in routine child immunization program

Tel Aviv University researcher develops tool to measure tissue damage in bed-ridden, paralyzed patients

Human stem cells restore alveolar epithelial tissue after E. coli endotoxin-induced ALI: Researchers

BioMS reports consolidated net income of $6.5M for first-quarter 2010 compared to net loss of $3.8M in 2009

Experts address fundamental questions related to renal failure in ICU

MRSA Survivors Network to raise awareness on MRSA infections

Benefits outweigh risks in myeloablative therapy for children with high-risk neuroblastoma

Opinions: Abortion in Canada's G8 initiative; Security of Afghan women; U.S. global development strategy; Mother's Day; U.S. food security initiative; Polio eradication

Astute Medical completes $26.5 million series B financing

Lancet examines Canada's G8 strategy for maternal, child health initiatives

Allos Therapeutics reports net loss of $20.5 million for first-quarter 2010

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Sepsis News and Research

Latest Sepsis News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in